Pharmacogenomics of Sickle Cell Disease: Pain and Drug metabolism associated Gene Variants, and hydroxyurea-induced miRNAs


Background: The major therapeutic benefit of hydroxyurea (HU), the only FDA-approved pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant... [ view full abstract ]


  1. Khuthala Mnika (University of Cape Town)
  2. Wonkam Ambroise (University of Cape Town)
  3. Emile Chimusa (University of Cape Town)
  4. Collet Dandara (University of Cape Town)
  5. Shaheen Mowla (University of Cape Town)

Topic Areas

Personalized therapies (cancer, immunology, infectious diseases, clinical case studies, et , Emerging opportunities in personalized medicine, cutting-edge new strategies and solutions


PS1 » Poster Session (14:00 - Monday, 25th June, Main hall)

Presentation Files

The presenter has not uploaded any presentation files.